Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2018
Price : $35 *
At a glance
- Drugs RNS 60 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 15 Jul 2018 Status changed from recruiting to completed.
- 11 Nov 2014 Planned number of patients changed from 15 to 16 as reported by European Clinical Trials Database.
- 12 Nov 2013 New trial record